Processa Pharmaceuticals, Inc. (PCSA) Balance Sheet

The consistent decline in total assets over the last ten quarters suggests that the company is consuming its capital base at a rate that outpaces its ability to replenish it through financing. This trajectory indicates that the business model remains entirely dependent on external capital injections, which may become increasingly difficult to secure given the lack of commercial progress.

A current ratio falling below 1.0 is a concerning indicator for a clinical-stage biotech, as it suggests that current liabilities may soon exceed the available liquid assets. Investors should monitor this trend closely, as it implies that the company may face immediate pressure to raise capital or restructure its clinical trial obligations to avoid a liquidity crisis.

The persistent growth in negative retained earnings highlights the high cost of the company's R&D-heavy strategy and the lack of commercial success to date. This trend suggests that the equity base is being systematically hollowed out, which may necessitate further dilutive equity offerings to maintain operations, thereby pressuring existing shareholders.